Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NeoRx's radiotherapy proves safe in high doses:

This article was originally published in Clinica

Executive Summary

NeoRx plans to treat bone cancer patients with the highest doses of its Skeletal Targeted Radiotherapy (STR) product in a Phase III trial, following positive results from a Phase I study. Even at the highest doses of STR, multiple myeloma patients showed no significant side effects, according to the Seattle, Washington-based company, which has nearly completed a Phase II trial. The product, a drug that delivers the radionuclide holmium-166 to bone, could provide an intensive and effective treatment for older patients and its may also potentially be used to treat other diseases such as prostate cancer, said NeoRx.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT073010

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel